1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Striatonigral Atrophy in 12 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A levodopa-responsive parkinsonism emerged in all MPTP-treated monkeys." | 5.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| " Chronic administration of MPTP induces lesion via apoptosis." | 1.38 | Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. ( Arun, A; Donmez, G; Ellis, L; Liu, L; Peritore, C, 2012) |
| "A levodopa-responsive parkinsonism emerged in all MPTP-treated monkeys." | 1.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, A | 1 |
| Yamaguchi, H | 1 |
| Yamasaki, R | 1 |
| Cui, Y | 1 |
| Matsuoka, Y | 1 |
| Yamada, KI | 1 |
| Kira, JI | 1 |
| Benskey, M | 1 |
| Behrouz, B | 1 |
| Sunryd, J | 1 |
| Pappas, SS | 1 |
| Baek, SH | 1 |
| Huebner, M | 1 |
| Lookingland, KJ | 1 |
| Goudreau, JL | 1 |
| Liu, L | 1 |
| Arun, A | 1 |
| Ellis, L | 1 |
| Peritore, C | 1 |
| Donmez, G | 1 |
| Tan, LC | 1 |
| Protell, PH | 1 |
| Langston, JW | 1 |
| Togasaki, DM | 1 |
| Ghorayeb, I | 2 |
| Fernagut, PO | 4 |
| Stefanova, N | 2 |
| Wenning, GK | 3 |
| Bioulac, B | 2 |
| Tison, F | 4 |
| Crocker, SJ | 1 |
| Smith, PD | 1 |
| Jackson-Lewis, V | 1 |
| Lamba, WR | 1 |
| Hayley, SP | 1 |
| Grimm, E | 1 |
| Callaghan, SM | 1 |
| Slack, RS | 1 |
| Melloni, E | 1 |
| Przedborski, S | 1 |
| Robertson, GS | 1 |
| Anisman, H | 1 |
| Merali, Z | 1 |
| Park, DS | 1 |
| Puschban, Z | 1 |
| Brouillet, E | 1 |
| Reindl, M | 1 |
| Jellinger, KA | 1 |
| Poewe, W | 2 |
| Diguet, E | 1 |
| Kaku, K | 1 |
| Shikimi, T | 1 |
| Kamisaki, Y | 1 |
| Shinozuka, K | 1 |
| Ishino, H | 1 |
| Okunishi, H | 1 |
| Takaori, S | 1 |
| Aubert, I | 1 |
| Bezard, E | 1 |
| Pearce, RK | 1 |
| Costa, S | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Eberling, JL | 1 |
| Pivirotto, P | 1 |
| Bringas, J | 1 |
| Bankiewicz, KS | 1 |
12 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Striatonigral Atrophy
| Article | Year |
|---|---|
Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Annexin A2; Astrocytes; Calcium-Binding Prote | 2018 |
Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine; Dopamine Plasma Memb | 2012 |
Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Apoptosis; Apoptosis Regulatory | 2012 |
The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Female; Hyperkinesis; L | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2002 |
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Aged; Aged, 80 and over; Animals; Behavi | 2003 |
Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2003 |
MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Corpus Striatum | 2004 |
Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corticosterone; Dopamine Agents; Interleukin- | 1999 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Callithrix | 1999 |
Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Dopamine Agents; F | 2000 |